MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317617 | Name: Diltiazem free base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Diltiazem is a nondihydropyridines (non-DHP) calcium channel blocker used in the treatment of hypertension, angina pectoris, and some types of arrhythmia. It relaxes the smooth muscles in the walls of arteries, which opens (dilates) the arteries, allows blood to flow more easily, and lowers blood pressure.

Chemical Structure

Diltiazem free base
CAS#42399-41-7 (free base)

Theoretical Analysis

MedKoo Cat#: 317617

Name: Diltiazem free base

CAS#: 42399-41-7 (free base)

Chemical Formula: C22H26N2O4S

Exact Mass: 414.1613

Molecular Weight: 414.52

Elemental Analysis: C, 63.75; H, 6.32; N, 6.76; O, 15.44; S, 7.73

Price and Availability

Size Price Availability Quantity
100mg USD 150.00 Ready to ship
200mg USD 250.00 Ready to ship
500mg USD 450.00 Ready to ship
1g USD 750.00 Ready to ship
2g USD 1,250.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
42399-41-7 (free base) 144604-00-2 (malate) 33286-22-5 (HCl) 139492-78-7 (maleate)
Synonym
CRD 401; CRD-401; CRD401; Diltiazem; Dilticard; Dilzen
IUPAC/Chemical Name
(2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
InChi Key
HSUGRBWQSSZJOP-RTWAWAEBSA-N
InChi Code
InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
SMILES Code
O=C1[C@H](OC(C)=O)[C@H](C2=CC=C(OC)C=C2)SC3=CC=CC=C3N1CCN(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#S8B03T01
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Diltiazem is an L-type Ca2+ channel blocker.
In vitro activity:
Treatment with diltiazem inhibited the proliferation and suppressed the mobility of MHCC97H and 7402 cells in a time- and concentration-dependent manner (P < 0.05). Treatment with 100 μmol/L diltiazem for 24 h significantly inhibited the proliferation of MHCC97H cells and down-regulated the mRNA and protein levels of TMEM16A. In 7402 cells, diltiazem treatment at 50 μmol/L for 48 h resulted in the most significant inhibitory effect on the cell proliferation and TMEM16A expressions. The results suggest that diltiazem can transiently inhibit the invasion of hepatocellular carcinoma cells in vitro possibly by down-regulating the expression of TMEM16A at both the mRNA and protein levels. Reference: Nan Fang Yi Ke Da Xue Xue Bao. 2018 Jul 30;38(7):818-823. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765537/
In vivo activity:
The hypothesis that the calcium ion (Ca2+ ) channel blocker diltiazem (DTZ) reduces contraction-induced skeletal muscle damage was tested in B6.A-Dysfprmd /GeneJ (BLAJ) mice, which model human limb-girdle muscular dystrophy 2B (LGMD2B). DTZ improved contractile torque before and immediately after forced eccentric contractions, but did not reduce delayed-onset muscle damage that was observed at 3 days after eccentric contractions. Reference: Physiol Rep. 2018 Jun;6(11):e13727. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995314/

Preparing Stock Solutions

The following data is based on the product molecular weight 414.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Guo R, Huang X, Jin X, Yang J. [Diltiazem inhibits proliferation and motility of hepatocellular cells in vitro by downregulating calcium-activated chloride channel TMEM16A]. Nan Fang Yi Ke Da Xue Xue Bao. 2018 Jul 30;38(7):818-823. Chinese. doi: 10.3969/j.issn.1673-4254.2018.07.08. PMID: 33168514; PMCID: PMC6765537. 2. Watts TJ. The in vitro hemolytic effect of diltiazem on erythrocytes exposed to varying osmolarity. Toxicol Mech Methods. 2010 Oct;20(8):435-9. doi: 10.3109/15376516.2010.491519. PMID: 20486888.
In vitro protocol:
1. Guo R, Huang X, Jin X, Yang J. [Diltiazem inhibits proliferation and motility of hepatocellular cells in vitro by downregulating calcium-activated chloride channel TMEM16A]. Nan Fang Yi Ke Da Xue Xue Bao. 2018 Jul 30;38(7):818-823. Chinese. doi: 10.3969/j.issn.1673-4254.2018.07.08. PMID: 33168514; PMCID: PMC6765537. 2. Watts TJ. The in vitro hemolytic effect of diltiazem on erythrocytes exposed to varying osmolarity. Toxicol Mech Methods. 2010 Oct;20(8):435-9. doi: 10.3109/15376516.2010.491519. PMID: 20486888.
In vivo protocol:
1. Guo R, Huang X, Jin X, Yang J. [Diltiazem inhibits proliferation and motility of hepatocellular cells in vitro by downregulating calcium-activated chloride channel TMEM16A]. Nan Fang Yi Ke Da Xue Xue Bao. 2018 Jul 30;38(7):818-823. Chinese. doi: 10.3969/j.issn.1673-4254.2018.07.08. PMID: 33168514; PMCID: PMC6765537. 2. Watts TJ. The in vitro hemolytic effect of diltiazem on erythrocytes exposed to varying osmolarity. Toxicol Mech Methods. 2010 Oct;20(8):435-9. doi: 10.3109/15376516.2010.491519. PMID: 20486888.
1: Wang L, Cheng Z, Gu Y, Peng D. Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int. 2015;2015:382086. doi: 10.1155/2015/382086. Epub 2015 Oct 4. Review. PubMed PMID: 26504804; PubMed Central PMCID: PMC4609355. 2: Sajid MS, Whitehouse PA, Sains P, Baig MK. Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure. Colorectal Dis. 2013 Jan;15(1):19-26. doi: 10.1111/j.1463-1318.2012.03042.x. Review. PubMed PMID: 22487078. 3: Kubo Y, Fukumoto D, Ishigami T, Hida Y, Arase S. Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review. J Dermatol. 2010 Sep;37(9):807-11. doi: 10.1111/j.1346-8138.2010.00858.x. Review. PubMed PMID: 20883365. 4: Budriesi R, Ioan P, Carosati E, Cruciani G, Zhorov BS, Chiarini A. Ligands of diltiazem binding site: an overview of some chemotypes. Mini Rev Med Chem. 2009 Oct;9(12):1379-88. Review. PubMed PMID: 19929811. 5: Fernández-Ruiz M, López-Medrano F, García-Ruiz F, Rodríguez-Peralto JL. [Diltiazem-induced acute generalized exanthemic pustulosis: a case and review of the literature]. Actas Dermosifiliogr. 2009 Oct;100(8):725-7. Review. Spanish. PubMed PMID: 19775556. 6: Ezeugo U, Glasser SP. Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases. Expert Opin Pharmacother. 2009 Feb;10(3):485-91. doi: 10.1517/14656560802694739 . Review. PubMed PMID: 19191683. 7: Sajid MS, Rimple J, Cheek E, Baig MK. The efficacy of diltiazem and glyceryltrinitrate for the medical management of chronic anal fissure: a meta-analysis. Int J Colorectal Dis. 2008 Jan;23(1):1-6. Epub 2007 Sep 11. Review. PubMed PMID: 17846781. 8: Claas SA, Glasser SP. Long-acting diltiazem HCl for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris. Expert Opin Pharmacother. 2005 May;6(5):765-76. Review. PubMed PMID: 15934903. 9: Fedele F, Cacciotti L, Di Donato D, Addonisio L, Musarò S, Lavalle C. [Diltiazem in acute coronary syndromes]. Cardiologia. 1999 Dec;44 Suppl 1(Pt 1):319-22. Review. Italian. PubMed PMID: 12497928. 10: Soares KV, McGrath JJ. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000;(2):CD000206. Review. PubMed PMID: 10796323. 11: Pool PE. Anomalies in the dosing of diltiazem. Clin Cardiol. 2000 Jan;23(1):18-23. Review. PubMed PMID: 10680025. 12: O'Connor SE, Grosset A, Janiak P. The pharmacological basis and pathophysiological significance of the heart rate-lowering property of diltiazem. Fundam Clin Pharmacol. 1999;13(2):145-53. Review. PubMed PMID: 10226758. 13: Iagenskiĭ VA, Grosu AA. [Verapamil and diltiazem in the treatment of atrial fibrillation]. Ter Arkh. 1997;69(8):58-60. Review. Russian. PubMed PMID: 9381395. 14: Odeh M. Exfoliative dermatitis associated with diltiazem. J Toxicol Clin Toxicol. 1997;35(1):101-4. Review. PubMed PMID: 9022661. 15: Kjeldsen SE, Syvertsen JO, Hedner T. Cardiac conduction with diltiazem and beta-blockade combined. A review and report on cases. Blood Press. 1996 Sep;5(5):260-3. Review. PubMed PMID: 8879597. 16: Dagenais F, Hollmann C, Buluran J, Cartier R. Clentiazem and diltiazem preserve endothelium-dependent relaxation following global rat heart ischemia. Can J Cardiol. 1995 Oct;11(9):816-22. Review. PubMed PMID: 7585280. 17: Traverse JH, Swenson LJ, McBride JW. Acute hepatic injury after treatment with diltiazem. Am Heart J. 1994 Jun;127(6):1636-9. Review. PubMed PMID: 8197999. 18: Markham A, Brogden RN. Diltiazem. A review of its pharmacology and therapeutic use in older patients. Drugs Aging. 1993 Jul-Aug;3(4):363-90. Review. PubMed PMID: 8369596. 19: Roper TA, Sykes R, Gray C. Fatal diltiazem overdose: report of four cases and review of the literature. Postgrad Med J. 1993 Jun;69(812):474-6. Review. PubMed PMID: 8208646; PubMed Central PMCID: PMC2399841. 20: Beleslin DB, Prostran MS, Jovanović-Mićić D. [Pharmacology--new therapy. Calcium channel blockers: new aspects of therapeutic use of diltiazem]. Srp Arh Celok Lek. 1992 May-Jun;120(5-6):188-92. Review. Serbian. PubMed PMID: 1465675.